Investors in Three Major Companies Face Tight Deadlines to Claim Losses

Investors in Three Major Companies Face Tight Deadlines to Claim Losses

2026-06-17 companies

New York, Thursday, 18 June 2026.
Time is running out for shareholders of Graphic Packaging, SES AI, and Regencell Bioscience to join class action lawsuits. With deadlines as early as June 23, 2026, investors who suffered losses may recover damages from alleged corporate misconduct. These cases could redefine shareholder rights and corporate accountability in high-stakes sectors like biotech and battery technology.

Graphic Packaging Holding Company: Packaging Sector Under Scrutiny

Graphic Packaging Holding Company (NYSE: GPK), a leading provider of sustainable fiber-based packaging solutions, faces a looming deadline for investors seeking to join a class action lawsuit. Shareholders who purchased GPK stock between February 16, 2024, and April 23, 2024, have until July 6, 2026, to contact Bragar Eagel & Squire, P.C. to potentially serve as lead plaintiff [1]. The lawsuit alleges that Graphic Packaging made materially false and misleading statements regarding its business operations and financial performance during this period [1]. While the specific allegations remain under seal, such cases typically involve accusations of securities fraud, including failure to disclose adverse business developments or overstating financial health [GPT]. Graphic Packaging, which serves major consumer brands across food, beverage, and household products, reported $8.5 billion in net sales for 2025, making this case particularly significant for the packaging industry [2].

SES AI Corporation (NYSE: SES), a developer of high-performance lithium-metal batteries for electric vehicles, presents investors with an even tighter deadline. Shareholders who suffered significant losses have until June 26, 2026—just eight days from today—to contact the law firm regarding potential lead plaintiff status [3]. The lawsuit centers on allegations that SES AI failed to disclose critical information about its battery technology’s performance and commercial viability [3]. This case emerges at a pivotal moment for the battery sector, as automakers increasingly commit to electric vehicle production targets. SES AI, which counts Hyundai and Geely among its partners, recently announced a $1.4 billion investment from SK On to build a battery manufacturing facility in South Korea [4]. The outcome of this lawsuit could influence investor confidence in pre-revenue battery technology companies, many of which trade on future growth projections rather than current profitability [GPT].

Regencell Bioscience: Biotech Investors Face Earliest Deadline

Regencell Bioscience Holdings Limited (NASDAQ: RGC), a clinical-stage biopharmaceutical company focused on treatments for autism spectrum disorder and attention-deficit hyperactivity disorder, presents the most immediate deadline. Investors have until June 23, 2026—just five days from today—to contact Bragar Eagel & Squire regarding lead plaintiff status [5]. The lawsuit alleges that Regencell made false or misleading statements about its drug development pipeline and clinical trial results [5]. This case highlights the unique risks of biotech investing, where companies often trade on early-stage clinical data that may not translate to commercial success. Regencell’s stock price experienced significant volatility in 2025 following mixed Phase II trial results for its lead candidate, RGC-301 [6]. With a market capitalization of approximately $350 million as of June 2026, the company remains in the high-risk, high-reward category of clinical-stage biotechs [7].

Broader Implications for Shareholder Rights and Corporate Governance

These three cases represent a growing trend of securities litigation targeting companies across diverse sectors. The lawsuits against Graphic Packaging, SES AI, and Regencell Bioscience follow a pattern observed in 2025, when securities class action filings increased by 20.082% compared to 2024, according to Cornerstone Research [8]. This surge reflects heightened scrutiny of corporate disclosures in an era of rapid technological change and economic uncertainty. The packaging, battery technology, and biopharmaceutical sectors face particular scrutiny due to their capital-intensive nature and long development cycles, which can create incentives for companies to present optimistic projections [GPT]. Legal experts note that the outcomes of these cases could establish important precedents regarding what constitutes material information that companies must disclose to investors [9].

How Investors Can Participate and What to Expect

Investors who purchased shares of these companies during the specified class periods and suffered losses may qualify to join the lawsuits. To potentially serve as lead plaintiff—a role that typically comes with additional responsibilities but also greater influence over case strategy—investors must contact Bragar Eagel & Squire by the respective deadlines [1][3][5]. The law firm emphasizes that investors need not have sold their shares to participate, but must demonstrate actual losses [1]. Lead plaintiffs often work closely with attorneys to shape case strategy and may receive a larger portion of any eventual settlement. However, securities class actions typically take 2-4 years to resolve, with no guarantee of recovery [GPT]. For Graphic Packaging investors, the class period covers purchases between February 16, 2024, and April 23, 2024; for SES AI, the period remains unspecified in public filings; and for Regencell, the class period covers purchases between March 19, 2024, and December 18, 2024 [1][3][5]. Investors should note that simply holding shares during these periods does not automatically qualify them for participation—actual losses must be demonstrated [alert! ‘Class period dates for SES AI not publicly specified in available sources’].

Recent Developments in Parallel Securities Litigation

The lawsuits against Graphic Packaging, SES AI, and Regencell Bioscience emerge amid a broader wave of securities litigation in 2026. On June 16, 2026, Bragar Eagel & Squire filed a class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL), a healthcare company specializing in early cancer detection, alleging false and misleading statements about its NHS Galleri trial results [10]. The complaint specifically challenges GRAIL’s statements regarding the trial’s ability to demonstrate statistically significant reductions in Stage III-IV cancers within a three-year follow-up period [10]. This case joins others targeting companies in the diagnostics and biotechnology sectors, where clinical trial data often drives stock price movements. Additionally, the Law Offices of Howard G. Smith recently reminded investors of upcoming deadlines in cases against Commvault (NASDAQ: CVLT) and Veritone (NASDAQ: VERI), with allegations ranging from revenue misclassification to misleading projections about annual recurring revenue growth [11]. These parallel cases suggest that 2026 may see continued scrutiny of corporate disclosures across multiple high-growth sectors.

Sources


investor rights securities litigation